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B lastic plasmacytoid dendritic cell neoplasm (BPDCN), formerly known as CD4 + /CD56 + hematodermic neoplasm or blastic natural killer (NK) cell lymphoma, is an exceedingly rare and highly aggressive malignant neoplasm, recently reclassified as a distinct entity. 1, 2 It shows a strong predilection for elderly men but may affect any age group, including neonates. 2, 3 Because the skin is usually the site of initial presentation, dermatologists play a key role in timely recognition and treatment. 2, 4, 5 Cutaneous involvement is invariably followed by rapidly progressing systemic dissemination, which may culminate in fulminant leukemia.
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The response to high-dose chemotherapy and/or radiotherapy is initially favorable but ultimately short lived, and median survival rarely exceeds 14 months. [2] [3] [4] [5] [6] Occasionally, allogeneic bone marrow transplantation has achieved sustained remission in younger patients.
2,4-6
The diagnosis of BPDCN is rendered difficult by the heterogeneity of clinical and immunophenotypic features. [1] [2] [3] [4] [5] [6] CONCLUSIONS AND RELEVANCE Expression of CD31/PECAM-1 by BPDCN adds new information about the antigenic profile of this unusual neoplasm. CD31/PECAM-1 influences multiple cell functions including adhesion, apoptosis, coagulation, host response, and protein synthesis that might affect clinical features of BPDCN such as hemorrhage, aggressive tumor growth, and resistance to therapy. Therefore, the potential role of this molecule in the tumor formation and progression of BPDCN warrants additional exploration.
5,7
Herein we report the expression of CD31/PECAM-1 (platelet endothelial cell adhesion molecule 1) as an additional antigenic characteristic of BPDCN.
Report of Cases
Our study was initiated by the results of the immunohistochemical (IHC) analysis of a violaceous nodule with surrounding golden contusiform rim on the shoulder of an otherwise asymptomatic 80-year-old man ( Figure 1A) . Histopathologic examination revealed a dense dermal infiltrate of uniform, mononuclear cells in the absence of other inflammatory cells, necrosis, or angioinvasion ( Figure 1B) . Differential diagnostic considerations included hematopoietic and lymphoid malignant neoplasms, as well as vascular tumors, necessitating a broad panel of antibody tests. Samples stained for IHC analysis were positive for CD4, CD56, CD123, and CD31 ( Figure 2) and negative for CD2, CD3, CD5, CD7, CD8, T-cell-restricted intracellular antigen 1 (TIA-1), CD20, PAX-5, lysozyme, myeloperoxidase, CD30, CD1a, CD68, and terminal deoxynucleotidyl transferase. A complete blood cell count with differential, comprehensive metabolic panel and serum as well as urine protein electrophoresis had normal results. A computed tomographic scan showed a 5 × 2-cm lesion of the right side of the chest and a 1.7-cm-diameter splenic mass. The clinical and IHC findings were consistent with BPDCN. This case was reminiscent of that of a former patient of ours with BPDCN, whose tumor cells were also CD31 positive. 8 The aforementioned observations prompted us to investigate the expression of CD31 by BPDCN cells. In collaboration with 3 other tertiary care institutions, 8 additional patients with BPDCN were identified and paraffin-embedded lesional tissue sections were subjected to immunoperoxidase IHC analysis for the CD31 protein in accordance with manufacturer-recommended protocols, using monoclonal mouse anti-human CD31 antibodies (clone JC/70A, isotype IgG1κ) from Biocare Medical, Dako North America, and Thermo Scientific. Tumor cells demonstrated strong immunoreactivity in 6 cases, paralleling the IHC results seen in Figure 2 , whereas 2 cases had negative results. To exclude low-level protein expression undetectable by IHC analysis, the negative biopsy samples were subjected to multispectral image analysis, which has been demonstrated to be more sensitive than routine IHC analysis in the assessment of low-level protein ex- sence of CD31 in 1 case, whereas the other case showed small clusters of weakly positive cells, which most likely represented admixed macrophages. The expression of CD31 by intratumoral macrophages has been described as a potential diagnostic pitfall in the evaluation of tumor tissue sections for the presence of this antigen. 10 In view of this fact, and because more than 95% of the tumor cell infiltrate in this biopsy sample was nonreactive, we designated it CD31 negative without further investigation. Taken together with our previously published report, 8 IHC analysis detected strong, widespread expression of CD31 by neoplastic cells in 8 of 10 BPDCN cases (80%).
Discussion
Two major subtypes of circulating dendritic cell (DC) populations have been identified to date: myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). Formerly thought to originate from NK cells, BPDCN is now believed to derive from pDC precursors, as evidenced by the expression of pDC antigens TCL1, CD123, and BDCA-2. CD31 is best known as a marker for vascular components of tissues (both normal and diseased) because it is expressed on early and mature endothelial cells and related neoplasms. However, it is also present on platelets and some plasma cells, monocytes, immature mDCs, neutrophils, NK cells, and lymphocytes. 11 In addition, CD31 expression has been observed commonly in some nonendothelial cancers, predominantly in leukemias and lymphomas such as acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, mantle cell lymphoma, hairy cell leukemia, and multiple myeloma but not in cutaneous T-cell lymphomas. [11] [12] [13] Approximately one-third of uterine cervical carcinomas are CD31 + , and it is also expressed occasionally by a wide variety of other carcinomas and sarcomas. 11, 12 We are contributing an additional type of neoplasm, BPDCN, to the list of nonendothelial malignancies that express CD31 frequently. However, because of the rarity of this neoplasm, it will be important to study additional cases to determine whether the true prevalence of CD31 expression is 80% (8 of 10) as we report here. CD31 is able to engage in heterophilic as well as in homophilic binding, allowing complex adhesive interactions, which represent a basis for the role of this molecule in vascular biology. 11 Our observation raises the question of whether CD31 on tumor cells might bind to CD31 on platelets, thereby inhib- 
